Pharma transactions during the COVID-19 pandemic
How resilient were they?
whitepaper
Provided by
With deal volumes in pharma going against forecasts and rising significantly during the pandemic, this paper takes a close look at how deal flow was maintained during such tough working conditions. Of course, new processes played a big role. But so did the attitudes and resilience of those individuals involved who had to adapt to such unfamiliar conditions.
This paper explores the:
• Use of technology, from zoom to digital signatures
• Subsequent increased scrutiny on cyber security and business continuity
• Impact on contract negotiation, speed of decision making and people
• Post pandemic world and what it could hold for deals in pharma going forward
